← Back to Search

Anti-tumor antibiotic

Combination Chemotherapy for Prostate Cancer

Phase 1
Waitlist Available
Research Sponsored by Herbert Irving Comprehensive Cancer Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Hepatic: Bilirubin no greater than upper limit of normal, Alkaline phosphatase no greater than 5 times ULN, SGOT and SGPT no greater than 2 times ULN
At least 4 weeks since prior chemotherapy
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights

Study Summary

This trial is testing different combinations of chemotherapy drugs to see what works best and what the side effects are in treating prostate cancer.

Who is the study for?
This trial is for adults with advanced prostate cancer who have not responded to hormone therapy. They should have new or growing tumors, confirmed adenocarcinoma of the prostate, rising PSA levels, or new bone scan lesions. Participants must be in good physical condition with a life expectancy over 3 months and no severe health issues like heart failure, significant infections, or other cancers within the last 5 years.Check my eligibility
What is being tested?
The study is testing how well different chemotherapy drugs work together to treat advanced prostate cancer. It aims to find out the best doses that can be given safely without causing severe side effects by gradually increasing doses for new groups of patients.See study design
What are the potential side effects?
Chemotherapy may cause side effects such as fatigue, nausea, hair loss, increased risk of infection due to low blood cell counts, mouth sores, and potential damage to organs like the liver and kidneys depending on drug specifics.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
My liver tests are within normal limits.
Select...
It has been over 4 weeks since my last chemotherapy session.
Select...
I am 18 years old or older.
Select...
I do not have any current infections.
Select...
I do not have any serious illnesses besides my current condition.
Select...
My kidney function, measured by creatinine, is within normal limits.
Select...
I have no history of blood clotting disorders, recent heart attacks, strokes, or heart failure.
Select...
I have never had a pulmonary embolism.
Select...
I am able to get out of my bed or chair and move around.
Select...
I don't have uncontrolled diabetes or active stomach ulcers.
Select...
My prostate cancer is getting worse despite hormone therapy.
Select...
My cancer has not spread to my brain or its coverings.
Select...
My prostate cancer has been confirmed by a tissue examination.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Find a Location

Who is running the clinical trial?

Herbert Irving Comprehensive Cancer CenterLead Sponsor
33 Previous Clinical Trials
917 Total Patients Enrolled
2 Trials studying Prostate Cancer
142 Patients Enrolled for Prostate Cancer
Daniel P. Petrylak, MDStudy ChairHerbert Irving Comprehensive Cancer Center
5 Previous Clinical Trials
1,234 Total Patients Enrolled
3 Trials studying Prostate Cancer
1,197 Patients Enrolled for Prostate Cancer

Media Library

Doxorubicin (Anti-tumor antibiotic) Clinical Trial Eligibility Overview. Trial Name: NCT00003633 — Phase 1
Prostate Cancer Research Study Groups:
Prostate Cancer Clinical Trial 2023: Doxorubicin Highlights & Side Effects. Trial Name: NCT00003633 — Phase 1
Doxorubicin (Anti-tumor antibiotic) 2023 Treatment Timeline for Medical Study. Trial Name: NCT00003633 — Phase 1

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is this experiment currently recruiting participants?

"At this juncture, the clinical trial listed on clinicaltrials.gov is not actively recruiting participants; having been first posted in August 1998 and last updated December 2013. Notwithstanding, there are 1321 other medical trials currently enrolling patients."

Answered by AI

To what extent does this therapy pose possible risks to patients?

"Since this is the initial phase of testing, there's only minimal evidence that supports safety and efficacy which led to a rating of 1."

Answered by AI
~0 spots leftby Mar 2025